SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Ledermann Jonathan A.)
 

Sökning: WFRF:(Ledermann Jonathan A.) > Symptom burden and ...

  • Lee, Yeh ChenAustralia New Zealand Gynaecol Oncol Grp ANZGOG, Australia; Univ Sydney, Australia; Univ New South Wales, Australia (författare)

Symptom burden and quality of life with chemotherapy for recurrent ovarian cancer : the Gynecologic Cancer InterGroup-Symptom Benefit Study

  • Artikel/kapitelEngelska2022

Förlag, utgivningsår, omfång ...

  • 2022-01-27
  • BMJ Publishing Group,2022
  • electronicrdacarrier

Nummerbeteckningar

  • LIBRIS-ID:oai:DiVA.org:liu-182926
  • https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-182926URI
  • https://doi.org/10.1136/ijgc-2021-003142DOI
  • http://kipublications.ki.se/Default.aspx?queryparsed=id:148686866URI

Kompletterande språkuppgifter

  • Språk:engelska
  • Sammanfattning på:engelska

Ingår i deldatabas

Klassifikation

  • Ämneskategori:ref swepub-contenttype
  • Ämneskategori:art swepub-publicationtype

Anmärkningar

  • Funding Agencies|NHMRCNational Health and Medical Research Council of Australia [1063012, 570893]; Target Ovarian Cancer [UCL-P001AL]; Cancer Research UKCancer Research UK; UCL Cancer Trials Centre [C444/A15953]; Australian Government through Cancer AustraliaAustralian Government; NHMRC Program grantNational Health and Medical Research Council of Australia; Department of HealthEuropean Commission
  • Objective The Gynecologic Cancer InterGroup (GCIG)-Symptom Benefit Study was designed to evaluate the effects of chemotherapy on symptoms and health-related quality of life (HRQL) in women having chemotherapy for platinum resistant/refractory recurrent ovarian cancer (PRR-ROC) and potentially platinum sensitive with >= 3 lines of chemotherapy (PPS-ROC >= 3). Methods Participants completed the Measure of Ovarian Cancer Symptoms and Treatment (MOST) and European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire QLQ-C30 questionnaires at baseline and every 3-4 weeks until progression. Participants were classified symptomatic if they rated >= 4 of 10 in at least one-third of symptoms in the MOST index. Improvement in MOST was defined as two consecutive scores of <= 3 in at least half of the symptomatic items at baseline. Improvement in HRQL was defined as two consecutive scores >= 10 points above baseline in the QLQ-C30 summary score scale (range 0-100). Results Of 948 participants enrolled, 910 (96%) completed baseline questionnaires: 546 with PRR-ROC and 364 with PPS-ROC >= 3. The proportions of participants symptomatic at baseline as per MOST indexes were: abdominal 54%, psychological 53%, and disease- or treatment-related 35%. Improvement was reported in MOST indexes: abdominal 40%, psychological 35%, and disease- or treatment-related 38%. Median time to improvement in abdominal symptoms occurred earlier for PRR-ROC than for PPS-ROC >= 3 (4 vs 6 weeks, p=0.044); median duration of improvement was also similar (9.0 vs 11.7 weeks, p=0.65). Progression-free survival was longer among those with improvement in abdominal symptoms than in those without (median 7.2 vs 2.5 months, p<0.0001). Improvements in HRQL were reported by 77/448 (17%) with PRR-ROC and 61/301 (20%) with PPS-ROC >= 3 (p=0.29), and 102/481 (21%) of those with abdominal symptoms at baseline. Conclusion Over 50% of participants reported abdominal and psychological symptoms at baseline. Of those, 40% reported an improvement within 2 months of starting chemotherapy. Approximately one in six participants reported an improvement in HRQL. Symptom monitoring and supportive care is important as chemotherapy palliated less than half of symptomatic participants.

Ämnesord och genrebeteckningar

Biuppslag (personer, institutioner, konferenser, titlar ...)

  • King, Madeleine T.Univ Sydney, Australia (författare)
  • OConnell, Rachel L.Univ Sydney, Australia (författare)
  • Lanceley, AnneUCL, England (författare)
  • Joly, FlorenceGINECO Grp Investigateurs Nationaux Etud Canc Ova, France; Ctr Francois Baclesse, France (författare)
  • Hilpert, FelixArbeltsgesrneinschaft Gynakolog Onkol Studiengrp, Germany; North Eastern German Soc Gynecol Oncol NOGGO, Germany; Krankenhaus Jerusalem, Germany (författare)
  • Davis, AlisonAustralia New Zealand Gynaecol Oncol Grp ANZGOG, Australia; Canberra Hosp, Australia (författare)
  • Roncolato, Felicia T.Australia New Zealand Gynaecol Oncol Grp ANZGOG, Australia; Univ Sydney, Australia (författare)
  • Okamoto, AikouJapanese Gynecol Oncol Grp JGOG, Japan; Jikei Univ, Japan (författare)
  • Bryce, JaneIst Nazl Tumori IRCCS Fdn Pascale, Italy; Ascension St John Clin Res Inst, OK USA; MITO Multictr Italian Trials Ovarian & Gynecol Ca, Italy (författare)
  • Donnellan, PaulGalway Univ Hosp, Ireland (författare)
  • Oza, Amit M.Princess Margaret Consortium PMHC, Canada; Univ Toronto, Canada (författare)
  • Åvall-Lundqvist, Elisabeth,Professor,1957-Linköpings universitet,Avdelningen för kirurgi, ortopedi och onkologi,Medicinska fakulteten,Region Östergötland, Onkologiska kliniken US,Nord Soc Gynaecol Oncol NSGO, Denmark; Karolinska Inst, Sweden(Swepub:liu)eliav51 (författare)
  • Berek, Jonathan S.Cooperat Gynecol Oncol Investigators COGI, CA USA; Stanford Univ, CA 94305 USA (författare)
  • Ledermann, Jonathan A.Canc Res UK, England; NCRI UK, England (författare)
  • Berton, DominiqueGINECO Grp Investigateurs Nationaux Etud Canc Ova, France; Ctr Rene Gauducheau, France (författare)
  • Sehouli, JalidArbeitsgesmeinschaft Gynakol Onkol Studiengrp A, Germany; North Eastern German Soc Gynecol Oncol NOGGO, Germany; Charite Univ Med Berlin, Germany (författare)
  • Feeney, AmandaCanc Res UK, England; NCRI UK, England (författare)
  • Kaminsky, Marie-ChristineGINECO Grp Investigateurs Nationaux Etud Canc Ova, France; Inst Cancerol Lorraine, France (författare)
  • Diamante, KatrinaUniv Sydney, Australia (författare)
  • Stockler, Martin R.Univ Sydney, Australia (författare)
  • Friedlander, Michael L.Australia New Zealand Gynaecol Oncol Grp ANZGOG, Australia; Univ New South Wales, Australia (författare)
  • Australia New Zealand Gynaecol Oncol Grp ANZGOG, Australia; Univ Sydney, Australia; Univ New South Wales, AustraliaUniv Sydney, Australia (creator_code:org_t)

Sammanhörande titlar

  • Ingår i:International Journal of Gynecological Cancer: BMJ Publishing Group32:6, s. 761-7681048-891X1525-1438

Internetlänk

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy